vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v11i1.145vsp-523Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEЭФФЕКТИВНОСТЬ ПРИМЕНЕНИЯ ИНФЛИКСИМАБА В ТЕРАПИИ БОЛЕЗНИ КРОНА У ДЕТЕЙEFFICACY OFINFLIXIMABIN THE TREATMENTOF CROHN’S DISEASEIN CHILDRENЦимбаловаЕ. Г.TsimbalovaE. G.
Ekaterina Georgievna Tsimbalova, MD, senior research scientist of Gastroenterological and Hepatological Department of SCCH of RAMS
tsimbalova@list.ruПотаповА. С.PotapovA. S.tsimbalova@list.ruВенедиктоваМ. М.VenedictovaM. M.tsimbalova@list.ruШавровА. А.ShavrovF. F.tsimbalova@list.ruНаучный центр здоровья детей РАМН, МоскваРоссияScientific Research Center of Children’s Health RAMS, MoscowRussian FederationНаучный центр здоровья детей РАМН, Москва;
Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Research Center of Children’s Health RAMS, Moscow;
I.M. Sechenov First Moscow State Medical University, MoscowRussian Federation201215012012111Вопросы современной педиатрии135142Copyright © Цимбалова Е.Г., Потапов А.С., Венедиктова М.М., Шавров А.А., 20122012Цимбалова Е.Г., Потапов А.С., Венедиктова М.М., Шавров А.А.Tsimbalova E.G., Potapov A.S., Venedictova M.M., Shavrov F.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/523детиболезнь КроналечениеинфликсимабchildrenCrohn’s diseasetreatment with infliximabReferencesVilar P., de Carly J. M., Acuna C. E. et al. Infliximab in paediatric inflammatory bowel disease // JCC. — 2007; 1: 2–9.Vilar P., de Carly J. M., Acuna C. E. et al. Infliximab in paediatric inflammatory bowel disease // JCC. — 2007; 1: 2–9.The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Gert Van Assche at all, Eduard Stange for the European Crohn's and Colitis Organisation (ECCO) // Journal of Crohn's and Colitis. — 2010; 4: 7–27.The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Gert Van Assche at all, Eduard Stange for the European Crohn's and Colitis Organisation (ECCO) // Journal of Crohn's and Colitis. — 2010; 4: 7–27.Griffiths A. M. Specificities of inflammatory bowel disease in childhood // Best Pract. Res. Clin. Gastroenterol. — 2004; 18 (3): 509–523.Griffiths A. M. Specificities of inflammatory bowel disease in childhood // Best Pract. Res. Clin. Gastroenterol. — 2004; 18 (3): 509–523.Feagan B. G. Infliximab in the treatment of Crohn’s disease // Scand J. Gastroenterol. — 2000; 14 (Suppl. C): 6B.Feagan B. G. Infliximab in the treatment of Crohn’s disease // Scand J. Gastroenterol. — 2000; 14 (Suppl. C): 6B.Van Deventer S. Targeting TNF-a a key in the inflammatory process in Crohn’s disease — the mechanism of action of infliximab // Aliment Pharmacol Ther. — 1999; 13 (Suppl.): 43–48.Van Deventer S. Targeting TNF-a a key in the inflammatory process in Crohn’s disease — the mechanism of action of infliximab // Aliment Pharmacol Ther. — 1999; 13 (Suppl.): 43–48.Van A. G., Vermeire S., Rutgeerts P. Mucosal healing and anti- TNFs in IBD // Curr. Drag Targets. — 2010; 11: 227–233.Van A. G., Vermeire S., Rutgeerts P. Mucosal healing and anti- TNFs in IBD // Curr. Drag Targets. — 2010; 11: 227–233.Cornillie F., Shealy D., D’Haens G. et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease // Aliment Pharmacol. Ther. — 2001;15: 463–473.Cornillie F., Shealy D., D’Haens G. et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease // Aliment Pharmacol. Ther. — 2001;15: 463–473.de Ridder L., Benninga M. A., Taminiau Jan A. J. M. et al. Infliximab Use in Children and Adolescents With Inflammatory Bowel Disease // Journal of Pediatric Gastroenterology and Nutrition. — 2007; 43: 3–14.de Ridder L., Benninga M. A., Taminiau Jan A. J. M. et al. Infliximab Use in Children and Adolescents With Inflammatory Bowel Disease // Journal of Pediatric Gastroenterology and Nutrition. — 2007; 43: 3–14.Targan S., Hanauer S., Van Deventer S. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha-_ for Crohns disease // N. Engl. J. Med. — 1997; 337: 1029–1035.Targan S., Hanauer S., Van Deventer S. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha-_ for Crohns disease // N. Engl. J. Med. — 1997; 337: 1029–1035.Baldassano R. N., Vasiliauskas V., Braegger C. P. et al. A multicenter study of infliximab (anti-TNF alpha antibody) in treatment of children with active Crohn’s disease // Gastroenterology. — 1999; 116: A665.Baldassano R. N., Vasiliauskas V., Braegger C. P. et al. A multicenter study of infliximab (anti-TNF alpha antibody) in treatment of children with active Crohn’s disease // Gastroenterology. — 1999; 116: A665.Sterhes M. C., Speranski M. A., Manula P. et al. Safety and steroid-sparing experience using infliximad for Crohn’s disease at pediatric bowel disease center // Am. J. Gastroenterol. — 2003; 98 (1): 104–111.Sterhes M. C., Speranski M. A., Manula P. et al. Safety and steroid-sparing experience using infliximad for Crohn’s disease at pediatric bowel disease center // Am. J. Gastroenterol. — 2003; 98 (1): 104–111.Hanauer S. B., Feagan B. G., Lichtenstein G. R. et al. ACCENT 1 Study Group. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomized trial // Lancet. — 2002; 359: 1541–1549.Hanauer S. B., Feagan B. G., Lichtenstein G. R. et al. ACCENT 1 Study Group. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomized trial // Lancet. — 2002; 359: 1541–1549.Present D. H., Rutgeerts P., Targan S. et al. Infliximab to the treatment of fistulas in patients with Crohn's disease // N. Engl. J. Med. — 1999; 340: 1398–1405.Present D. H., Rutgeerts P., Targan S. et al. Infliximab to the treatment of fistulas in patients with Crohn's disease // N. Engl. J. Med. — 1999; 340: 1398–1405.Colombel J., Rutgeerts P., Reinisch W. et al. SONIC: A rando - mized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohns disease naiv to immunomodulators and biologic therapy // Gut. — 2008; 57 (Suppl. II): А-1.Colombel J., Rutgeerts P., Reinisch W. et al. SONIC: A rando - mized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohns disease naiv to immunomodulators and biologic therapy // Gut. — 2008; 57 (Suppl. II): А-1.Hyams J., Granball W., Kugathasan S. et al. Induction and maintenance infliximab therapy for the treatment of moderate-tosevere Crohn’s disease in children // Gastroenterology. — 2007; 132 (3): 863–873.Hyams J., Granball W., Kugathasan S. et al. Induction and maintenance infliximab therapy for the treatment of moderate-tosevere Crohn’s disease in children // Gastroenterology. — 2007; 132 (3): 863–873.Froslie K. F., Jahnsen J., Moum B. A. et al. Тhe IBSEN Group. Mucosal Healing in inflammatory Bowel Disease: results from a Norwegian population-based cohort // Gastroenterology. — 2007; 133: 412–422.Froslie K. F., Jahnsen J., Moum B. A. et al. Тhe IBSEN Group. Mucosal Healing in inflammatory Bowel Disease: results from a Norwegian population-based cohort // Gastroenterology. — 2007; 133: 412–422.Hyams J. S., Mandel F., Ferry G. D. et al. Developmen and validation of Pediatric Crohn’s disease activity index // J. Pediatr Gastroenterol. Nutr. — 1991; 12: 439–447.Hyams J. S., Mandel F., Ferry G. D. et al. Developmen and validation of Pediatric Crohn’s disease activity index // J. Pediatr Gastroenterol. Nutr. — 1991; 12: 439–447.Mary J. Y., Modiglamni R. Development and validation of an endoscopic index of severity for Crohn’s disease: a prospective multicentre study (GETAID) // Gut. — 1989; 30 (70): 983–989.Mary J. Y., Modiglamni R. Development and validation of an endoscopic index of severity for Crohn’s disease: a prospective multicentre study (GETAID) // Gut. — 1989; 30 (70): 983–989.Schnitzler F., Fidder H., Ferrante M. et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease // Inflamm Bowel Dis. — 2009; 15 (9): 1295–1301.Schnitzler F., Fidder H., Ferrante M. et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease // Inflamm Bowel Dis. — 2009; 15 (9): 1295–1301.Cheifetz A., Smedley M., Martin S. et al. The incidence and management of infusion reactions to infliximab: a large center experience // Am. J. Gastroenterol. — 2003; 98: 1315–1324.Cheifetz A., Smedley M., Martin S. et al. The incidence and management of infusion reactions to infliximab: a large center experience // Am. J. Gastroenterol. — 2003; 98: 1315–1324.Gardam M. A., Keystone E. C., Menzies R. et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management // Lancet infect Dis. — 2003; 3: 148–155.Gardam M. A., Keystone E. C., Menzies R. et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management // Lancet infect Dis. — 2003; 3: 148–155.
The authors declare that there are no conflicts of interest present.